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Background
Immune reconstitution inflammatory syndrome (IRIS) is
a set of conditions, characterized by findings of inflamma-
tion, which occur in HIV-infected patients after initiation
of antiretroviral therapy (ART). It is believed to result from
an overly exuberant response to residual opportunistic
pathogens by the newly reconstituted immune system.
Specific manifestations of IRIS depend upon the pathogen
being targeted, but among the variants of IRIS, Kaposi's
sarcoma-associated IRIS (KS-IRIS) is one of the least
understood – especially in resource-limited settings where
KS is epidemic. Now that ART is becoming available in
sub-Saharan Africa, we have hypothesized that KS-IRIS is
likely to be most relevant in this region. This is because of
the high prevalence of AIDS-related KS in sub-Saharan
Africa (i.e., large number of patients with AIDS-KS initiat-
ing ART) and because of factors that theoretically may pre-
dispose to KS-IRIS, specifically higher KS lesion burden
and lower pre-ART CD4+ T cell count.
Methods
In Kampala, Uganda, we studied the incidence and spec-
trum of KS-IRIS in a randomized trial for the initial ther-
apy of AIDS-related KS. Participants without indications
for chemotherapy were randomized to one of two differ-
ent ART regimens and then evaluated every 4 weeks for 48
weeks with a questionnaire, physical examination, and
digital photography to record signs and symptoms com-
patible with KS-IRIS. KS-IRIS was defined as development
of a) any of the following in pre-existing KS lesions: swell-
ing, pain or tenderness, paresthesia, erythema, or warmth;
or b) not otherwise explained subcutaneous nodules,
node enlargement, edema, or pleural effusion.
Results
Of the first 30 subjects evaluated, 17 (57%) exhibited ≥ 1
sign or symptom compatible with KS-IRIS. The most com-
mon finding was lesion swelling (43%), and there were
several instances of dramatic lesion enlargement followed
by spontaneous reduction (see Figures 1 and 2 from two
subjects). Other manifestations included lesion pain or
pares-thesia (33%), warmth or erythema (23%), femoral
or inguinal node enlargement with scrotal swelling (n =
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1), and pleural effusion (n = 1). The most fulminant KS-
IRIS case featured diffuse lesion swelling and new diffuse
subcutaneous nodules; death ensued but the causative
role of KS-IRIS is unknown. Of the three participants with
KS-IRIS that did not resolve spontaneously and who were
given chemotherapy, two had a good response to lipo-
somal doxorubicin.
Conclusion
In sub-Saharan Africa, KS-IRIS occurs at a clinically rele-
vant frequency with a wide spectrum of manifestations.
Many of the findings are difficult to distinguish in real
time from natural KS progression, and even some of the
most dramatic cases can be self-limiting. This, coupled
with the general lack of effective chemotherapy for KS in
resource-limited settings, makes patient management
complicated when KS-IRIS is suspected. In this setting,
diagnostic tests are thus urgently needed to distinguish
IRIS-based disease from natural progression of KS.
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